Rankings
▼
Calendar
JANX Q3 2024 Earnings — Janux Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena
JANX
Janux Therapeutics, Inc.
$852M
Q3 2024 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$439,000
-82.6% YoY
Gross Profit
$439,000
100.0% margin
Operating Income
-$36M
-8164.5% margin
Net Income
-$28M
-6391.6% margin
EPS (Diluted)
$-0.51
QoQ Revenue Growth
-95.1%
Cash Flow
Operating Cash Flow
-$2M
Free Cash Flow
-$2M
Stock-Based Comp.
$15M
Balance Sheet
Total Assets
$695M
Total Liabilities
$39M
Stockholders' Equity
$656M
Cash & Equivalents
$27M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$439,000
$3M
-82.6%
Gross Profit
$439,000
$2M
-78.2%
Operating Income
-$36M
-$16M
-126.7%
Net Income
-$28M
-$12M
-142.6%
← FY 2024
All Quarters
Q4 2024 →